Bifogade filer
PDF
The cancer diagnostics company BiBBInstruments AB ("BiBB"), the developer of the world's first market-cleared electric-driven biopsy instrument for endoscopy, today announces that the Company has received an Intention to Grant from the China National Intellectual Property Administration (CNIPA). The notice means that CNIPA intends to approve a patent application for EndoDrill[®] in the first patent family in China. Certain formalities will now follow before approval, after which the patent will be valid until October 2039.
BiBB has received an Intention to Grant from CNIPA regarding the approval of patent application CN2019800668466 from patent family 1 in China. The patent provides broad protection for the EndoDrill[®] product series in the Chinese market. The company has three international patent applications for EndoDrill[®] that have entered the national/regional phase, with patents already granted in Europe, Japan, and India, as well as Intention to Grant in China. Other patent applications will be pursued toward approval to provide global protection for the market's first electric-driven endoscopic biopsy instrument.
"The Intention to Grant our first patent in China is strategically important and strengthens our global IP portfolio, enhancing the potential for a successful global launch with a future partner," says Fredrik Lindblad, CEO of BiBB.
This is a translation of the Swedish press release. If there should be any discrepancies, the Swedish language version prevails.
For more information about BiBB, please contact:
Fredrik Lindblad, CEO
E-mail: fredrik.lindblad@bibbinstruments.com
Phone: +46 70 899 94 86
www.bibbinstruments.com
This disclosure contains information that BiBBInstruments AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on October 11, 2024.
About BiBB
The cancer diagnostics company BiBBInstruments AB develops and manufactures EndoDrill[®], a patented product line of electric-driven endoscopic biopsy instruments. The EndoDrill[®] instruments take high-quality tissue samples with high precision with the goal of improving the diagnosis of several serious cancers, such as stomach, pancreas, liver, lung, and bladder. The product portfolio is aimed at the global market for ultrasound-guided endoscopic (EUS/EBUS) biopsy instruments, which constitute the most advanced and fast-growing area of endoscopy. BiBB received 510(k) clearance from the US FDA for the lead product EndoDrill[®] GI in 2023. At the beginning of 2024, CE marking according to MDR was also obtained for all three product variants: EndoDrill® GI, EndoDrill[®] EBUS and EndoDrill[®] URO. Thus EndoDrill[®] is the first cleared electric endoscopic biopsy system in both the US and Europe. The EndoDrill[®] system includes sterile disposable biopsy instruments with associated drive system. The company was founded in 2013 by Dr. Charles Walther, cancer researcher at Lund University and senior consultant in clinical pathology at Skåne University Hospital in Lund. BiBBInstruments is based at Medicon Village in Lund and the BiBBInstruments share (ticker: BIBB) is listed on Spotlight Stock Market.